TC BioPharm Company Insiders
| TCBP Stock | USD 0.64 0.02 3.03% |
TC BioPharm employs about 41 people. The company is managed by 6 executives with a total tenure of roughly 96 years, averaging almost 16.0 years of service per executive, having 6.83 employees per reported executive. Discussion of TC BioPharm's management performance can provide insight into the enterprise performance.
TCBP |
TC BioPharm Management Team Effectiveness
The company has return on total asset (ROA) of (1.0892) % which means that it has lost $1.0892 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (12.1748) %, meaning that it created substantial loss on money invested by shareholders. TC BioPharm's management efficiency ratios could be used to measure how well TC BioPharm manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/26/2024, Return On Tangible Assets is likely to drop to -0.75. In addition to that, Return On Capital Employed is likely to drop to -3.58. At this time, TC BioPharm's Total Current Liabilities is relatively stable compared to the past year. As of 11/26/2024, Liabilities And Stockholders Equity is likely to grow to about 10 M, while Non Current Liabilities Total is likely to drop slightly above 1.4 M.As of 11/26/2024, Common Stock Shares Outstanding is likely to grow to about 32.4 K, while Net Loss is likely to drop (1.7 M).
TC BioPharm Workforce Comparison
TC BioPharm Holdings is rated fourth in number of employees category among its peers. The total workforce of Health Care industry is at this time estimated at about 495. TC BioPharm holds roughly 41.0 in number of employees claiming about 8% of equities under Health Care industry.
TC BioPharm Insider Trading
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific TC BioPharm insiders, such as employees or executives, is commonly permitted as long as it does not rely on TC BioPharm's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases, TC BioPharm insiders must file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Randall Mark Edward over six months ago Acquisition by Randall Mark Edward of 70000 shares of TC BioPharm subject to Rule 16b-3 |
TC BioPharm Notable Stakeholders
A TC BioPharm stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as TC BioPharm often face trade-offs trying to please all of them. TC BioPharm's stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting TC BioPharm's stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Michael MBA | CoFounder Chairman | Profile | |
| Lauren Bor | Head Division | Profile | |
| Martin Thorp | CFO Director | Profile | |
| Christopher Camarra | Executive Communications | Profile | |
| Bryan Kobel | CEO Director | Profile | |
| Angela Scott | CoFounder COO | Profile |
About TC BioPharm Management Performance
The success or failure of an entity such as TC BioPharm Holdings often depends on how effective the management is. TC BioPharm management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of TCBP management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the TCBP management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.71) | (0.75) | |
| Return On Capital Employed | (3.41) | (3.58) | |
| Return On Assets | (0.66) | (0.69) | |
| Return On Equity | (2.20) | (2.09) |
TC BioPharm Workforce Analysis
Traditionally, organizations such as TC BioPharm use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare TC BioPharm within its industry.TC BioPharm Manpower Efficiency
Return on TC BioPharm Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 144.1K | |
| Net Loss Per Executive | 984.5K | |
| Working Capital Per Employee | 23.2K | |
| Working Capital Per Executive | 158.4K |
Additional Tools for TCBP Stock Analysis
When running TC BioPharm's price analysis, check to measure TC BioPharm's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy TC BioPharm is operating at the current time. Most of TC BioPharm's value examination focuses on studying past and present price action to predict the probability of TC BioPharm's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move TC BioPharm's price. Additionally, you may evaluate how the addition of TC BioPharm to your portfolios can decrease your overall portfolio volatility.